Background: Diarrhea is one of the most disturbing effects of chemotherapy, affecting quality of life on the one hand and .limiting applicable doses on the other. Irinotecan (CPT-11) and 5-fluorouracil (5-FU) are associated with an elevated risk of developing severe diarrhea. Standard therapy consists of highdose loperamide, but is associated with frequent failure. Other therapeutic regimens are still experimental. Endoscopic examination of a patient with severe loperamide-resistant diarrhea after CPT-11 chemotherapy revealed an inflammation of the ileo-coecal region. Oral therapy with the topical corticosteroid budesonide was immediately effective. This led to a phase I study of budesonide in CPT-11-and 5-FU-induced and loperamide-refractory diarrhea.
Introduction
After nausea and vomiting, diarrhea is still one of the most disturbing side effects of chemotherapy with respect to quality of life. 5-Fluorouracil (5-FU) and especially irinotecan (CPT-11) are associated with a higher risk of developing grade 3-4 (WHO/NCI) delayed diarrhea than that of other cytotoxic drugs [1] [2] [3] [4] [5] . CPT-11-induced diarrhea has been categorized as secretory type with reduced intestinal fluid absorption and an exsudative component [6, 7] . It appears to result from a direct toxic action of irinotecan and its active metabolite SN-38 on the intestinal mucosa after biliary excretion [5, 8, 9] . Delayed diarrhea in CPT-11 tends to be partially dosedependent [5] and less pronounced in a weekly schedule than in a three-week schedule [10] .
Standard anti-diarrheal treatment consists of highdose loperamide (2 mg every two hours) which decreases the incidence of severe diarrhea with CPT-11 to a range between 9% and 30% [2, 11, 12] . Other treatment options include the combination of loperamide and acetorphan [6] , which appeared to reduce significantly the incidence of severe diarrhea with a three-week schedule of CPT-11 in a small cohort ot patients. Octreotide, a long-acting somatostatin analogue, is also often effective but expen-* Presented in part on the 35th annual meeting of the American Society of Clinical Oncology, 15-18 May 1999, Atlanta, GA, USA.
sive [3, 13] and it failed to protect patients against diarrhea in a weekly regimen of 5-FU plus high-dose folinic acid [14] . Interleukin 15 offered significant protection against 5-FU/folinic acid-and CPT-11-induced diarrhea in a preclinical animal model [15, 16] .
A different approach has been developed after performance of colonoscopy in patients with CPT-11-associated diarrhea. The appearance of the mucosa in the terminal ileum and proximal colon with a slight erythema and increased vulnerability was in accord with findings in inflammatory bowel disease (IBD). In parallel we saw some patients with 5-FU-induced diarrhea and endoscopically-proven mild to severe duodenitis and ileitis.
The treatment of IBD, especially of Crohn's disease, is usually based on the use of steroids to ameliorate disease-associated diarrhea, especially in the acute phase. Budesonide is a non-halogenated glucocorticoid with a topical anti-inflammatory activity. Special galenic formulations ensure a targeted release of the orally administered substance in the terminal ileum and ascending colon. A 90% first-pass effect in the liver reduces systemic activity to a minimum of 10%. Budesonide is active in medium grade Crohn's disease and ulcerative colitis [17] [18] [19] [20] . The recommended dose is 9 mg/day [18] , usually taken in the morning.
Observation of the dramatic reduction of diarrhea frequency with the administration of budesonide after failure of loperamide in a CPT-11-treated patient, and the IBD-like mucosal appearance in the terminal ileum and ascending colon, prompted us to investigate the efficacy of topical budesonide in chemotherapy-induced diarrhea.
Study design

Entry criteria
• Presence of advanced colorectal cancer.
• Grade 3-4 diarrhea with weekly irinotecan (70 mg/m 2 ) or weekly high-dose 5-fluorouracil/folinic acid (2500/500 mg/m 2 ) 24-hour treatment.
• Failure of orally administered loperamide (4 mg initially, followed by 2 mg every 4 hours for 24 to 48 hours [3] ) to reverse or significantly reduce the frequency of diarrhea.
• No clinical sign of concurrent intestinal bacterial infection requiring antibiotic treatment.
• Compliance with taking budesonide and monitoring of stool frequency.
• Informed consent.
Drugs and drug administration
Three capsules of 3 mg budesonide (Entocort®, ASTRA GmbH, Wedel, Germany; Budenofalk®, Falk Pharma, Freiburg, Germany) were given as one daily dosing in the morning. No further increase in dose intensity was allowed in the protocol.
Duration of budesonide administration
Patients were instructed to maintain budesonide intake until resolution of the diarrheal symptoms. Budesonide administration was discontinued in instances of no reduction of diarrhea frequency after 48-72 hours. Patients responding to budesonide with irinotecan and no documented side effects received budesonide prophylactically (three capsules of 3 mg as described above) in subsequent treatment courses for three to five days, commencing with the day of drug administration.
Patient chracteristics
Fourteen patients (eleven men, three women) had budesonide after failure of loperamide with irinotecan, their median age was 58 years (range 53-71 years).
Seven patients (five men, two women) had budesonide after failure of loperamide with 5-FU, their median age was 59 years (range 54-69 years).
Results
Twenty-one patients were treated according to the study protocol.
In 86% of patients with irinotecan-induced severe diarrhea administration of budesonide after failure of loperamide resulted in a reduction of stool frequency by at least two grades according to the NCI/WHO classification (Table 1) . Four of seven patients receiving 5-FU showed a reduction of diarrhea frequency by at least two grades, and two additional patients by one grade (Table 1 ). In the majority of patients budesonide was effective within 24-48 hours.
All patients with positive response to budesonide treatment were successfully treated with budesonide if given as a prophylactic regimen.
No hematological or peripheral side effects were documented with the use of budesonide. There was no difference in efficacy between the used products (Entocort®, Budenofalk®) in this small cohort of patients, although according to the literature there seems to be a difference in drug release area (ileum up to ascending colon for Entocort®, ileum up to transverse colon for Budenofalk®).
In one patient budesonide had to be discontinued because of a preexisting small bowel bacterial overgrowth and no change in diarrhea frequency.
Conclusions
This is the first report about the activity of orally administered budesonide to reduce the frequency of diarrhea associated with irinotecan or 5-FU chemotherapy.
Chemotherapy-induced diarrhea is usually the result of multiple factors which cause an imbalance between secretion and absorption [3] . A high incidence of severe diarrhea after chemotherapy with 5-FU and irinotecan has been reported, and is often cited as the dose-limiting toxicity [2] . High-dose loperamide has proven to reduce the incidence of severe diarrhea with CPT-11 to a range between 9% and 30% [2, 11] . Octreotide is often effective [3, 13] , but it is expensive and requires several subcutaneous injections a day, which hampers patient compliance. Other preclinical [15, 16] and clinical studies are still experimental, as drugs such as acetorphan [6] or JBT 3002 [21] are not routinely applicable.
Ikuno et al. showed in experiments with a mouse model that CPT-11 may produce characteristic mucosal changes, especially in the terminal ileum and coecum [7] , the former being the predilection site for Crohn's disease. The observed changes are likely to cause malabsorption of water and electrolytes and hypersecretion ' of mucin. These structural and functional effects are probably the main causes of CPT-11-induced diarrhea. Saliba et al. [6] reported on a patient with persistent severe diarrhea who had undergone colonoscopy 12 days after CPT-11 administration. They described a diffuse congestive erythematous mucosa with multiple superficial small ulcerations which was completely resolved within 21 days. Neither differential involvement of different parts of the colon nor the pattern of the terminal ileum was described. It is known that people with a history of IBD have a greater risk of severe diarrhea while on treatment with 5-FU [22] .
This study was initiated after an endoscopicallyvisible IBD-like mucosal appearance of the ileo-coecal region caused by CPT-11 chemotherapy. On the basis of the experimental data, budesonide proved capable of decreasing inflammatory activity, which resulted in a dramatic reduction in stool frequency.
The study results demonstrate that oral budesonide is active in CPT-11-and 5-FU-induced diarrhea after loperamide failure, and also as prophylactic treatment. The use of budesonide may avert hospitalization for grade 4 diarrhea and excessive fluid loss. Patient compliance with the convenient once-a-day administration seems to be higher than that with loperamide administration. Budesonide could be the drug of choice for the prophylaxis of CPT-11-associated diarrhea. It should be emphasized that early initiation of treatment of chemotherapy-induced diarrhea may play a crucial role [6] . A high frequency and prolonged duration of diarrhea can lead to an insufficient intestinal contact time of orally applied therapeutics.
Daily drug costs for budesonide (9 mg) are currently Euro 6.0 s USS6.4 which is a reasonable price for averting hospitalization, parenteral fluid administration or a generally significant decrease in quality of life. Confirmation of budesonide's potential to reverse, reduce or prevent diarrhea with irinotecan chemotherapy in ongoing studies would represent major progress in supportive care.
Budesonide is generally available for the oral treatment of IBD in Canada and many European countries, but not in the USA.
